New mRNA vaccine candidates for RSV enter human testing
NCT ID NCT07071558
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-stage study tested six different mRNA vaccine formulations against respiratory syncytial virus (RSV) in 240 healthy adults aged 18 to 49. The goal was to check safety and how well the vaccines trigger an immune response. Each participant received a single shot and was followed for about six months.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- mRNA vaccine targeting RSV (respiratory syncytial virus)
- What this could lead to
- If successful, this could help develop a safe and effective mRNA vaccine to protect against RSV, a common respiratory virus.
- What could go wrong
- This is an early phase 1 study focused on safety, not effectiveness. The vaccine may not produce strong immunity or could cause side effects.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Phase 1
The first testing in people. Mainly checks safety and dose, usually in a small group.
- Participants
-
240 people
The number who actually took part.
- Started
-
Jul 2025
- Finished
-
Mar 2026
- Lead sponsor
-
A company
The lead sponsor is a pharmaceutical, biotech, or medical-device company.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 to 49 years
- Sex
-
Anyone
- Healthy volunteers
-
Accepted
You do not need to have the condition being studied to take part.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Aged 18 to 49 years on the day of inclusion * A female participant is eligible to participate if she is not pregnant or breastfeeding and of the following conditions applies: * Is of NCBP (Non-Child-Bearing Potential). To be considered of NCBP, a female must be post-menopausal for at least 1 year, or surgically sterile. OR * Is of CBP (Child-Bearing Potential) and agrees to use an effective contraceptive method or abstinence from at least 4 weeks prior to study intervention administration until at least 12 weeks after study intervention administration. Exclusion Criteria: * Any condition which, in the opinion of the Investigator, might interfere with the evaluation of the study objectives * The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Respiratory syncytial virus immunization are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Site # 0361001
Camberwell, Victoria, 3124, Australia
-
Site # 0361002
Bayswater, Victoria, 3153, Australia
-
Site # 0361003
Wollongong, New South Wales, 2500, Australia
-
Site # 0361004
Southport, Queensland, 4215, Australia
-
Site # 0361005
Morayfield, Queensland, 4506, Australia
-
Site # 0361006
Brisbane, Queensland, 4006, Australia
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new vaccine shield older adults from RSV?
- One shot, two viruses: could a combined vaccine shield seniors from RSV and HMPV?
- RSV shot uptake under the microscope: how many german babies get protected?
- Double defense: new mRNA vaccine targets two lung viruses in seniors
- New RSV shots slash baby hospitalizations? study digs into Real-World data